NASDAQ:BBIO - BridgeBio Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $67.25
  • Forecasted Upside: 8.08 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$62.22
▼ -0.3 (-0.48%)
1 month | 3 months | 12 months
Get New BridgeBio Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BBIO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$67.25
▲ +8.08% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $67.25, with a high forecast of $91.00 and a low forecast of $38.00. The average price target represents a 8.08% upside from the last price of $62.22.
Buy
The current consensus among 9 contributing investment analysts is to buy stock in BridgeBio Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2021MizuhoBoost Price TargetBuy$56.00 ➝ $86.00Low
i
2/22/2021JPMorgan Chase & Co.Initiated CoverageOverweightMedium
i
2/9/2021The Goldman Sachs GroupReiterated RatingBuy$83.00 ➝ $83.00Low
i
1/11/2021HC WainwrightBoost Price TargetBuy$64.00 ➝ $87.00High
i
12/14/2020BTIG ResearchBoost Price TargetBuy$49.00 ➝ $91.00High
i
12/10/2020HC WainwrightBoost Price TargetBuy$53.00 ➝ $64.00Low
i
12/4/2020SVB LeerinkBoost Price TargetOutperform$39.00 ➝ $44.00Medium
i
12/2/2020MizuhoBoost Price TargetBuy$51.00 ➝ $56.00High
i
11/5/2020Piper SandlerBoost Price TargetOverweight$50.00 ➝ $60.00Low
i
10/12/2020HC WainwrightBoost Price TargetBuy$50.00 ➝ $53.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/6/2020BMO Capital MarketsBoost Price TargetOutperform$44.00 ➝ $49.00High
i
9/30/2020The Goldman Sachs GroupBoost Price Target$43.00 ➝ $52.00High
i
8/12/2020HC WainwrightReiterated RatingBuy$50.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/25/2020Bank of AmericaInitiated CoverageNeutral$38.00High
i
6/11/2020HC WainwrightReiterated RatingBuy$50.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/19/2020BTIG ResearchInitiated CoverageBuy$49.00Low
i
5/14/2020SVB LeerinkLower Price TargetOutperform$41.00 ➝ $39.00High
i
4/13/2020HC WainwrightInitiated CoverageBuy$50.00High
i
Rating by R. Selvaraju at HC Wainwright
3/3/2020JPMorgan Chase & Co.Boost Price TargetOverweight$38.00 ➝ $43.00Low
i
2/18/2020MizuhoInitiated CoverageBuy$51.00High
i
1/7/2020Raymond JamesBoost Price Target$36.00 ➝ $40.00Low
i
Rating by Dane Leone at Raymond James
12/3/2019UBS GroupInitiated CoverageReduceHigh
i
10/18/2019Piper Jaffray CompaniesDropped CoverageBuy$50.00N/A
i
Rating by Tyler Van Buren at Piper Jaffray Companies
7/26/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$36.00High
i
7/22/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$34.00High
i
Rating by M. Foroohar at SVB Leerink LLC
7/22/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$38.00High
i
7/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$38.00High
i
7/22/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$50.00High
i
7/22/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$42.00High
i
7/22/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$49.00High
i
(Data available from 3/7/2016 forward)
BridgeBio Pharma logo
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; and UC San Francisco. The company was founded in 2015 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $62.22
$57.71
$63.00

50 Day Range

MA: $66.04
$55.47
$72.35

52 Week Range

Now: $62.22
$14.23
$73.50

Volume

865,910 shs

Average Volume

1,158,612 shs

Market Capitalization

$9.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of BridgeBio Pharma?

The following Wall Street sell-side analysts have issued research reports on BridgeBio Pharma in the last year: Bank of America Co., BMO Capital Markets, BTIG Research, HC Wainwright, JPMorgan Chase & Co., Mizuho, Piper Sandler, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for BBIO.

What is the current price target for BridgeBio Pharma?

8 Wall Street analysts have set twelve-month price targets for BridgeBio Pharma in the last year. Their average twelve-month price target is $67.25, suggesting a possible upside of 8.1%. BTIG Research has the highest price target set, predicting BBIO will reach $91.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $38.00 for BridgeBio Pharma in the next year.
View the latest price targets for BBIO.

What is the current consensus analyst rating for BridgeBio Pharma?

BridgeBio Pharma currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BBIO will outperform the market and that investors should add to their positions of BridgeBio Pharma.
View the latest ratings for BBIO.

What other companies compete with BridgeBio Pharma?

How do I contact BridgeBio Pharma's investor relations team?

BridgeBio Pharma's physical mailing address is 421 Kipling Street, Palo Alto CA, 94301. The company's listed phone number is 650-391-9740. The official website for BridgeBio Pharma is bridgebio.com.